RNA Metabolism and Therapeutics in Amyotrophic Lateral Sclerosis by Pansarasa, Orietta et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
RNA Metabolism and 
Therapeutics in Amyotrophic 
Lateral Sclerosis
Orietta Pansarasa, Stella Gagliardi, Daisy Sproviero  
and Cristina Cereda
Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neuromuscular disorder 
characterized by the selective death of upper and lowers motor neurons in spinal 
cord, brain stem, and motor cortex, which leads to paralysis and death within 
2–3 years of onset. Deeply sequencing technologies, to simultaneously analyze the 
transcriptional expression of thousands of genes, offered new possibilities to focus 
on ALS pathogenesis and, most notably, to find new potential targets for novel 
treatments. The present book chapter illustrates recent advances in transcriptomic 
studies in animal models and human samples and in new molecular targets related 
to ALS pathogenesis and disease progression. Additionally, new insights into the 
involvement of altered transcriptional profiles of noncoding RNAs (microRNA 
and lncRNA) and ALS-associated ribosomal binding proteins have been investi-
gated, to understand the functional consequences of extensive RNA dysregulation 
in ALS. Attention has been also turned on how transcriptome alterations could 
highlight new molecular targets for drug development.
Keywords: ALS, RNA metabolism, transcriptomics, gene expression,  
noncoding RNA
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurodegenerative 
disorder (ND) that affects the human motor system, that is, the lower and upper 
Highlights
• Aberrant RNA metabolism is one of the major contributors to ALS pathogenesis.
• Understanding RNA-binding protein functions and identifying target RNA regulatory networks is 
crucial to deepen ALS knowledge and to develop new therapeutics.
• miRNAs are strongly linked to the development of ALS and are indicated as new potential biomarkers.
• lncRNAs have been recently indicated to play important roles in CNS in health and disease such as ALS.
• miRNA-based therapeutics as well as deregulated AS are considered important areas for therapeutic 
intervention.
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motor neurons (MNs). Among the symptoms of ALS, there are progressive muscle 
weakness and paralysis, swallowing difficulties, and breathing impairment due 
to respiratory muscle weakness that finally causes death, within 2–5 years follow-
ing clinical diagnosis [1]. Now, also extramotor systems are involved in ALS, thus 
providing new insight into the pathogenesis of the disease. So far, no effective 
therapy is available for ALS: Rilutek (riluzole) and Radicava (edaravone) are the 
only two drugs approved by the Food and Drug Administration for ALS treatment. 
Unfortunately their effect in slowing disease progression is very modest [2]. The 
majority of ALS cases, named as sporadic (sALS), has no a family history; a fraction 
of cases (about 5–10%) are considered familial (fALS) [3], because of mutations in 
genes involved in a wide range of cellular functions. 60–70% of fALS and 10% of 
sporadic ALS (sALS) cases can be ascribed to mutations in SOD1, TARDBP, FUS, 
VCP, C9ORF72, and OPTN [4]; further rare genetic variants have also been identi-
fied, MATR3, HNRNPA1, HNRNPA2/B1, EWSR1, TAF15, ANG, UBQLN2, VAPB, 
TBK1, SQSTM1, PFN1, TUBA4A, KIF5A, ANXA11, and CHCHD10 [5]. Although an 
in-depth understanding of the mechanisms underlying ALS has yet to be reached, a 
growing interest was addressed to the impairment of RNA metabolism as one of the 
major contributor to ALS pathogenesis. This concept is reinforced by the discovery 
of genetic mutations in FUS and in TARDBP genes coding for RNA binding proteins 
(RBPs), which play a multifaceted role in transcription and in maintaining RNA 
metabolism. Recent studies have reported that a substantial portion of the genome 
is actively transcribed as noncoding RNA molecules. These noncoding RNAs are 
fundamental key actors in the regulation of biological processes and function as 
a “fine switch” of gene expression. It is now recognized that dysregulations in the 
noncoding RNAs gene expression is a putative mechanism in several neurological 
disorders, including ALS. Moreover, noncoding RNAs are emerging as new poten-
tial biomarkers contributing to an early disease diagnosis and treatment follow-up. 
To date, miRNA have been one the main focus of most ALS studies. miRNAs are 
differentially expressed in several tissues (CSF, plasma and serum) in ALS patients 
compared to healthy controls.
In this chapter, we will focus on the involvement of altered transcriptional 
profiles of microRNAs (miRNAs) and long noncoding RNA (lncRNA) as well as 
on ALS-related RNA binding proteins. We also review biomarkers and potential 
therapeutic strategies based on the manipulation of noncoding RNAs.
2. Dysfunctions in RNA metabolism and RNA-binding protein
It is broadly recognized that an aberrant RNA metabolism may contribute to 
RNA toxicity, which is due to the accumulation of toxic RNAs and to the dysfunc-
tion of RBPs [6].
Messenger RNAs (mRNAs) are subjected to several processing steps including 
splicing, polyadenylation, editing, transport, translation, and turnover. All these 
processes are extremely dynamic and require the involvement of RBPs to coordinate 
both co- and posttranscriptional processing of transcripts. Understanding RBPs 
functions and identifying their target RNA regulatory networks are crucial to 
deepen the knowledge in NDs and to promptly develop new therapeutics.
Nussbacher and colleagues by a genome-wide approach, have shed a new light 
on how RBPs may affect the fate of their targets [7]. Considering the great impact 
of RBPs on the expression, splicing, and translation of multiple RNA targets, also 
little changes in their expression and/or activity have amplified effects. Moreover, 
an altered interaction between RBPs and their targets can induce serious pathologi-
cal phenotypes, even if the exact mechanism is not clear. Briefly, we focus on RBPs, 
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TARDBP and FUS, and SOD1 and C9orf72 to highlight recent progresses on their 
involvement in RNA dysregulation.
TDP-43 is a heterogeneous nuclear RBP of 414 amino acids that contains two 
RNA recognition motifs (RRM1-2), a glycine rich domain in the C-terminus and 
nuclear localization and export signals (NLS and NES) [8, 9]. TDP-43 is crucial 
in RNA processing, that is, RNA splicing, transcription, transport, stability, as 
well as miRNA production [10]. TDP-43 binds to more than 6000 RNA targets in 
the brain [11, 12]. TDP-43 binds to mRNA and regulates the expression of other 
proteins: FUS, Tau, ATXN2 CHMP2B, VAPB, and progranulin, all involved in 
ALS and in other NDs [12, 13]. Polymenidou and colleagues using an RNA-seq 
approach, demonstrated the involvement of TDP-43 in the regulation of the 
expression of 239 mRNAs, many of those encoding synaptic proteins including 
neurexin NRXN1-3, neuroligin NLGN1-2, Homer2, microtubule-associated protein 
1B (MAP1B), GABA receptors subunits (GABRA2, GABRA3), AMPA receptor sub-
units (GRIA3, GRIA4), syntaxin 1B, and calcium channels [11, 14–17]. Together 
these data suggest the involvement of TDP-43 in neuronal morphology, synaptic 
transmission, and neuronal plasticity likely through the regulation of RNA pro-
cessing of synaptic genes [14]. TDP-43 is also a splicing regulator which decreases 
its own expression level by binding to the 3′-untranslated (UTR) region of its 
own pre-mRNA [18]. Moreover, its depletion or overexpression can influence the 
alternative splicing of specific targets genes, which are altered in ALS [11, 13, 19]. 
In 2012, Kawahara and Mieda-Sato also demonstrated the involvement of TDP-
43 in miRNA biogenesis. TDP-43 helps the production of the precursor miRNAs 
(pre-miRNAs) through the interaction of the Drosha complex and the binding to 
the primary miRNAs (pri-miRNAs) [20]. An increased expression of miR-633 and 
a decreased expression of the let-7b miRNA have been observed when TDP-43 is 
downregulated [21]. Moreover, TDP-43 binds to lncRNAs, including the nuclear-
enriched autosomal transcript 1 (NEAT1) and metastasis-associated lung adeno-
carcinoma transcript 1 (MALAT1) [13]. Until now, the exact role of this interaction 
is unclear; however both NEAT1 and MALAT1 levels are enhanced in patients with 
frontotemporal lobar degeneration (FTLD) and ALS [12, 22]. Nishimoto and co-
authors identified paraspeckles, that is, membraneless nuclear bodies, with high 
levels of NEAT1 and TDP-43 in MNs of patients in the early stage of the disease 
[22], thus interfering with TDP-43-mediated RNA processing and disrupting RNA 
homeostasis in ALS MNs.
FUS is an RBP of 526 amino acids mainly located in the nuclei. It is composed 
by an RNA recognition motif, a SYGQ (serine, tyrosine, glycine, and glutamine)-
rich region, several RGG (arginine, glycine, and glycine)-repeat regions, a C2C2 
zinc finger motif, and a nuclear localization signal (NLS) [23]. Similar to TDP-43, 
FUS has a key role in RNA processing. It is involved in transcriptional regulation, 
mRNA splicing, and miRNA production. FUS co-modulates certain transcription 
factors, including NF-kB, SPI1, and Runbox transcription factor (RUNX) [24, 25]. 
Genome-wide approaches have evidenced more than 5000 human RNA targets 
for FUS [26]. Considering that FUS is part of the hnRNP complex, it is crucial for 
the splicing mechanism [23], and it may affect the splicing mechanism of more 
than 900 mRNAs [26]. Among these, FUS may regulate the alternative splicing of 
genes related to cytoskeletal organization, axonal growth, and guidance such as 
the microtubule-associated protein tau (MAPT) [27], Netrin G1 (NTNG1) [28], 
neuronal cell adhesion molecule (NRCAM), and the actin-binding LIM (ABLIM1) 
[29]. Like TDP-43, FUS also binds to different mRNAs of ALS-related genes, 
VCP, VAPB, ubiquilin-2, and OPTN, thus modulating their expression [12, 26]. 
Furthermore, FUS is involved in the biogenesis of miRNA by recruiting Drosha to 
pri-miRNAs at their transcription sites and supports the biogenesis of a subset of 
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miRNAs [30]. However, if FUS directly regulates the function of mature miRNAs 
remains to be understand. Finally, FUS is crucial for the regulation of NEAT 1 levels 
and paraspeckle formation. FUS nuclear deficiency, its loss of nuclear function, as 
well as its aggregation might cause sequestration of paraspeckle components into 
pathological inclusions. Thus, the interaction between FUS and NEAT 1 is involved 
in the development of neuronal dysfunction in ALS [31].
SOD1 is not an RBP; however, several authors demonstrated that mutant SOD1 
has a role in RNA metabolism regulation [32, 33]. These authors reported that mutant 
SOD1 can bind mRNA species, that is, vascular endothelial growth factor (VEGF) 
and neurofilament light chain (NFL), and alter their expression, stabilization, and 
function [32, 33]. Mutant SOD1, by the direct bind to the 3’ UTR of VEGF mRNA, 
promotes the sequestration of other RBPs such as TIA-1-related protein (TIAR) and 
Hu antigen R (HuR) into insoluble aggregates. This, in turn, determines the impair-
ment of HuR function and interferes with the HuR neuroprotective effect during 
stress responses [32]. Chen and colleagues further demonstrated that, through the 
modification of neurofilament (NF) stoichiometry, mutant SOD1 destabilizes NFL 
mRNA. Consequently, NFs aggregate in MNs and are considered a hallmark of ALS 
disease [33]. NFL mRNA stability could also be regulated by a common interaction 
between SOD1 and TDP-43 [34]. The exact mechanism is not completely understood; 
however, it is hypothesized that mutant SOD1 removes TDP-43 from the NFL mRNA, 
thus disturbing NFL mRNA metabolism and promoting the formation of aggregates.
In 2011, the large GGGGCC hexanucleotide repeat expansion of C9orf72 has 
been recognized as a new cause of ALS [35, 36], accounting for about 50% of fALS 
and 5–10% of sALS [37]. The C9orf72 repeat expansion is transcribed in both the 
sense and antisense directions and causes the accumulations of repeat containing 
RNA foci [38]. RNA foci formation allows the recruitment of RBPs and alter RNA 
metabolism [39]. Mori and co-authors observed that RNA foci can sequester the RBP 
hnRNP-A3 and can suppress its RNA processing function. Notably, RNA foci are also 
able to sequester nuclear proteins such as TDP-43 and FUS, thus affecting the expres-
sion of their RNA targets, mainly involved in RNA metabolism, stress response, and 
nuclear transport. Moreover, RNA-Seq data unveil new candidate genes, that is, genes 
involved in synaptic transmission, protein targeting, and cell–cell signaling; however 
future validation are required [40]. Moreover, poly-PR and poly-GR can alter the 
splicing patterns of specific RNAs. The poly-PR causes the exon skipping in RAN and 
PTX3 RNA [41]. Finally, C9orf72 repeats can interfere with transcription or splicing 
of C9orf72 transcripts and can disrupt the C9orf72 promoter activity [42, 43].
3. Dysfunctions in RNA metabolism and miRNA
miRNAs are short noncoding RNAs, approximately 18–25 nucleotides long, that 
play a key role in the regulation of gene expression in many fundamental cellular 
processes and, posttranscriptionally, at the translation levels of target mRNA tran-
scripts [44, 45]. A high number of protein-coding genes have been demonstrated 
to be regulated by miRNA through base-pairing interactions within the UTR of the 
targeted mRNAs [46, 47]. Alongside their gene silencing functions, miRNAs can 
also induce upregulation of their targets [48]. An accurate regulatory pathway is 
fundamental to control and maintain the physiological processes of cells. However, 
when abnormalities occur, as in diseases, a complex dysregulation of the miRNA 
expression takes place. In this paragraph, we will focus on miRNAs which are linked 
to the development of ALS and miRNA with a potential role as biomarkers.
One of the most interesting miRNAs involved in ALS is miRNA206. miRNA206 
is skeletal muscle-specific, regulates myogenesis, and promotes the formation of 
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new neuromuscular junctions [49, 50]. Generally, the miRNA206 is overexpressed 
in muscle fibers and in serum of ALS patients [50, 51]. Pegoraro and co-authors 
associated the high levels of miRNA206 to the remodeling of the muscle, that 
is, atrophy, hypertrophy, and/or reinnervation of some fibers [51]. de Andrade 
et al. evidenced that miRNA206 increases early in the disease course and then 
decreases, thus suggesting its role during muscle loss [50]. miRNAs might also 
have a protective role in ALS; higher levels of miRNA206 were indeed observed in 
slow progressors, that is, in long-term ALS patients [52]. Thanks to the possibility 
to detect miRNA206 in accessible samples like serum and the correlation between 
miRNA206 levels and disease characteristics, miRNA206 could be indicated as a 
potential biomarker for ALS [53]. Other three miRNAs, miRNA133a/b, miRNA 1, 
and miRNA 27a, are indicated as muscle-specific. miRNA133 is higher in serum and 
muscle of ALS patients, and it is also higher in spinal ALS compared to bulbar ALS 
[51, 54]. An upregulation of miRNA27a was observed in CD14+ CD16− monocytes, 
in muscle fibers, and in CSF of ALS patients [51, 55], while a downregulation was 
reported in serum samples [54]. miRNA338-3p is another miRNA frequently 
upregulated. An increase of more than twofold was reported in leukocytes of 
sALS patients [56, 57]. Moreover, De Felice and co-authors showed an increase in 
miRNA338-3p in serum, CSF, and spinal cord of sALS patients. The evidence that it 
can be easily obtainable in body fluids suggested the possibility that miRNA338-3p 
might be a suitable biomarker for ALS. The inflammatory miRNA146a is overex-
pressed in CD14+ CD16− monocytes, CSF, spinal cord, and muscle fibers [55, 58]. 
miRNA146a can also interact with NFL mRNA 3′UTR, according to low mRNA 
levels observed in spinal neurons of sALS [58]. Tasca and co-authors, on the other 
hand, identified a reduction of miRNA146a in serum of ALS patients, both bulbar 
and spinal [54]. Tasca et al. and Pegoraro et al. found a downregulation in serum, 
muscle fibers, and leukocytes of sALS of the inflammatory miRNA149/149*. Also 
miRNA221 seems to contribute to ALS development by acting on muscle growth 
and/or atrophy and inflammation, through the NF-kB pathway [53, 54]. miRNA155 
was evaluated in CD14+ CD16− monocytes [55] and spinal cords of ALS patients, 
and it increases both in fALS and sALS [59]. Two other miRNAs targeting TGF-
β1, miRNA21, and miRNA106b were upregulated in CD14+ CD16− monocytes 
[55], and, at least for miRNA21, an upregulation was reported in muscle samples 
[50] in ALS patients even if its role in the pathology has yet to be fully explained. 
The same authors identified an inverse correlation between miRNA424 levels and 
disease progression, thus suggesting miRNA 424 as a potential biomarker [50] 
(Figure 1). The ALS genes, TDP-43 and FUS, play a role in miRNA biogenesis [60]. 
Mutations in TARDBP result in differential expression of miRNA9, miRNA132, 
miRNA143, miRNA558 [61], and let7 families [53], and differences between CSF 
and serum levels were observed. For instance, miRNA9, a brain-specific miRNA 
highly conserved during evolution is 2–3 times more elevated in CSF with respect to 
serum [62]. Differences are reported also for the presence of mutations. In induced 
pluripotent stem cell (iPSC)-derived neuron obtained from patients carrying the 
TARDBP p.A90V and the M337 V mutation, miRNA9 and pri-miRNA9-2 levels 
were lower when compared to controls [61]). Likewise, miRNA9 also decreases in 
lumbar motor neurons of sALS and SOD1 A4V mutated patients [63]. Moreover, 
a correlation between these miRNAs and disease duration and site of onset was 
identified. Specifically, miRNA 143-3p levels increase in later-collected samples, 
and the increase becomes significant in lower limb-onset patients [53] (Figure 2).
Morlando and co-authors reported that, upon FUS depletion, the expression of 
miRNA9, miRNA132, miRNA143, miRNA125, and miRNA192 is altered [30]. 
The involvement of these miRNAs in motor neuron development and maintenance, 
axonal growth, and synaptic transmission accounts for their contribution to the ALS 
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pathological phenotype [64, 65]. In motor neurons progenitors derived from human 
ALS iPSCs, Rizzuti et al. observed that miRNA34a and miRNA504, involved in vesicle 
regulation and cell survival, were dysregulated [66]. Also miRNA1825 is downregu-
lated in CNS of sALS and fALS patients, thus inducing depolymerization and degrada-
tion of tubulin alpha-4A (TUBA4A), which is encoded by the known ALS gene [67].
Taken together, these studies significantly contribute to evidence the importance 
of miRNAs, also as biomarkers for ALS. Despite these evidences, several issues 
need to be addressed mainly on the utility of miRNAs to serve as accurate and fast 
biomarkers for an early ALS diagnosis.
4. Dysfunctions in RNA metabolism and lncRNA
Long noncoding RNAs (lncRNAs) are transcripts, greater than 200 nucleotides 
in length, with no protein-coding potential which are found in sense or antisense 
Figure 1. 
Representation of the key miRNAs involved in amyotrophic lateral sclerosis sporadic patients (sALS).
Figure 2. 
Representation of the key miRNAs involved in amyotrophic lateral sclerosis mutated patients.
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orientation to protein-coding genes or within intergenic regions. lncRNAs control 
the gene expression through different mechanisms, that is, epigenetic modula-
tion through chromatin remodeling, activation or repression of transcription, 
posttranscriptional modifications of mRNA, and regulation of protein activity by 
acting as scaffold to recruit RBPs and/or drive RBPs to DNA. Moreover, they can 
compete for and disrupt protein-binding interactions or sponge miRNAs away from 
their mRNA targets [68]. Recently, lncRNAs have been indicated to play important 
roles in the CNS in health and disease such as ALS. Nishimoto and colleagues first 
identify a relation between NEAT1 and ALS pathogeneses [22]. The NEAT1 gene 
produces two transcripts, NEAT1_1 and NEAT1_2; NEAT1_2 expression is very 
low in the adult nervous system, and it is the only one that forms paraspeckles [69]. 
Specifically, NEAT1 acts as a scaffold for paraspeckles thus enhancing their de novo 
formation in spinal motor neurons in a cohort of sALS patients [22]. Paraspeckles 
function through the retention of specific RNAs; the regulation of gene expression 
by sequestration of transcription factors; and the modulation of miRNA biogenesis 
and mitochondrial function [70]. Paraspeckles are enriched in pathological proteins 
for ALS and are indicated as a hallmark of the disease [71]. Moreover, paraspeckle 
proteins, including TDP-43 and FUS, are related to ALS and FTD. The increase in 
paraspeckle formation in ALS could be triggered, at least in part, by the nuclear 
depletion of TDP-43. TDP-43 binds NEAT1, and, in turn, its downregulation stimu-
lates NEAT1_2 accumulation and paraspeckle association in cultured cells [71]. 
Regarding FUS, in the spinal cord of FUS mutated ALS patients, Shelkovnikova and 
co-authors reported the presence of pathological aggregation of NONO, a core para-
speckle protein [31]. This evidence allows to speculate that, considering that FUS 
and NONO are both required to set up paraspeckles, the formation of paraspeckles 
is disrupted in FUS mutated ALS patients. Also aberrant nuclear RNA foci formed 
by the expanded C9ORF72 repeats sequester paraspeckle proteins including TDP-43 
[72]. MALAT1 is abundantly expressed and evolutionarily conserved lncRNA. It 
is one of the first lncRNAs associated with human disease, and it is involved in 
alternative splicing, epigenetic modification of gene expression, synapse forma-
tion, and myogenesis. In NDs MALAT1 is significantly increased in FTLD patients, 
where it recruits splicing factors to nuclear speckles and affects phosphorylation of 
SR proteins37 [13]. Some lncRNA transcripts have been associated to FUS, among 
these the lncRNA CCND1 which binds to the FUS consensus sequence GGUG 
[73]. Data form Wang and colleagues suggested that FUS is a specific repressor of 
CCND1, which is downregulated in response to DNA damage signals. Until now the 
lncRNA CCND1 has not been described in relation to ALS; but taken together, these 
observations point out that this lncRNA could be, at least partly, responsible in ALS 
and other neurodegenerative diseases.
Together with the lncRNA an increasing interest was addressed to the antisense 
(AS) noncoding transcripts. They are generated from the strand opposite the sense 
strand [74]. AS lncRNAs act by regulating chromatin, by controlling DNA methyla-
tion and/or histones modification, or by removing repressors. They promote sense 
transcription by recruiting transcription factors, they also regulate the half-life 
of their sense partners, and, in turn, they regulate gene expression [74]. About 
70% of the human genome creates antisense transcripts with a great physiological 
and pathological significance. Ataxin 2 (ATXN2) is a coding gene related to ALS 
because of the association between the length of ATXN2 repeat expansion and the 
disease risk of ALS [75]. In 2016, Li and co-authors described the ATXN2-AS [76]. 
ATXN2-AS with its CUG repeat expansion is neurotoxic and may contribute to ALS 
pathogenesis. The CUG transcript toxicity is related to the structure formed by 
the repeats; that is, the stems of hairpin structures act with sponge-like features, 
sequester RBPs, and induce alterations of the RNA metabolism [77].
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Thanks to the deep sequencing technologies which allow high-throughput massive 
RNA sequencing, a wide characterization of the transcriptome profile of cell popula-
tions and tissues is now available. Three different massive transcriptome profiles have 
been published in different tissues (spinal cord, monocytes, and peripheral blood 
mononuclear cells) of ALS patients, and matched controls reported a deregulation in 
expressed genes [78, 79] and in lncRNAs [80]. Differences in transcriptome profiles 
(coding and lncRNAs) were observed in PBMCs of unmutated sALS patients, SOD1, 
TARDBP, and FUS mutated ALS patients and healthy controls [80]. Specifically, the 
authors reported a remarkable AS deregulation of genes involved in the transcription 
regulation pathway such as ZEB1-AS and ZBTB11-AS in sALS patients. ZEB1 acts as 
a repressor or an activator of the transcription, that is, it may repress histone organi-
zation or activate chromatin regulators [81]. As regards ZBTB11-AS, it decreases in 
sALS patients compared to healthy controls. ZBTB11-AS is annotated as AS of Zinc 
finger and BTB domain-containing protein 11 (ZBTB11) gene, and it is reported 
to be a negative regulator of cell cycle; however its exact role has yet to be defined 
[82]. Moreover, Gagliardi and co-authors evidenced UBXN7-AS, ATG10-AS, and 
ADORA2A-AS in sALS patients, all related to NDs [83–85]. Specifically, the regula-
tion of UBXN7, an ubiquitin protein bound by VCP a known ALS protein, through its 
AS controlled the ubiquitination in ALS disease. ATG10 is involved in the autophagy 
pathway, while ADORA2A is involved in Huntington’s disease and Parkinson’s disease 
in relation to defects in DNA methylation [84, 86] (Table 1).
5. Therapeutics
In the era of noncoding RNA, understanding the involvement of dysregulated 
miRNAs and of their targets in ALS disease is crucial to identify new pathways 
contributing to neurodegeneration that also offer novel opportunities for tar-
geted intervention. miRNA-based therapeutics take advantages of two different 
approaches. The first involves the use of an anti-miRNA, that is, chemically modi-
fied antisense RNA, to decrease miRNA. Thus, miRNA duplex is not active and 
counteracts the negative regulatory effects of miRNA. This approach was first 
used to deliver the anti-miR-155 to the SOD1G93A transgenic mice via ventricular 
osmotic pumps; after this treatment the mortality was successfully delayed [59]. 
The second therapeutic approach using miRNA involves miRNA mimics, that is, 
small RNA molecules resembling miRNA precursors, that are reintroduced into 
cells exhibiting downregulation thus re-starting the key-related pathways [87]. 
Biomedical and nanoparticle engineering has begun to develop tools allowing 
sALS TARDBP mutation FUS mutation
ATXN2-AS [76] NEAT1
[22, 69–71]
lncCCND1
[73]
ZEB1-AS [80] MALAT1
[13]
ZBTB11-AS [80]
UBXN7-AS [80]
ATG10-AS [80]
ADORA2A-AS [80]
Table 1. 
List of lncRNAs related to ALS. In square bracket the relative references.
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for this specific targeting. These second-generation miRNA-based therapeutics 
offer the potential for a greater delivery cargo to the tissue site while reducing 
RNA-mediated toxicity. Overall, the continued development of innovative RNA 
modifications and delivery items such as nanoparticles will aid in the development 
of future RNA-based therapeutics for a broader range of chronic disease.
Deregulated AS is considered an important area for therapeutic intervention. 
Particularly, gene therapy is an encouraging pharmacological approach for patients 
with diseases of genetic origins. This therapy is principally based on antisense oligo-
nucleotides (ASOs), spliceosome-mediated RNA trans-splicing (SMaRT), or small 
interfering RNAs (siRNAs) [88]. ASOs, that is, synthetic single-stranded nucleic 
acids, bind the pre-mRNA intron/exon junctions and control the splicing through 
their action on enhancers or repressor sequences, thus determining the skipping of 
the exon or including alternatively spliced exons [89].
In ALS, one of the first ASO-based clinical trials was designed to silence SOD1. 
The intrathecal administration of this ASO pass with good results the phase I test-
ing. Now a phase Ib/IIa trial is in process to assess safety, tolerability, and pharma-
cokinetics [90].
Among the ALS-related genes, C9orf72 is one of the best candidates for ASOs 
therapy. Early testing of ASO-based therapeutics for C9orf72 was performed on 
iPSC-derived neurons and fibroblasts [91]. Specifically, ASOs were designed to 
target the repeat expansion or within N-terminal regions of the mRNA transcript 
to destroy the transcript or to prevent the interaction between the repeat expan-
sion and the RBPs, determining a decrease in RNA foci and dipeptide proteins and 
recovering the normal gene expression [91]. Other studies investigated the effects of 
ASO on the oligonucleotide backbone, sugar, and heterocycles to promote delivery, 
potency, and stability to target FUS. These studies evidenced that the affinities of 
nucleic acid binding domains depend on chemical changes and that the interaction 
between ASO and protein affects the localization of ASOs themselves [92]. These 
data strongly indicate that ASO-based therapy could be central in treating ALS-
related genes, although there is great attention on the relation between the therapeu-
tic outcomes and the stage of disease progression and on the time of intervention.
Also many novel lncRNAs have been discovered, and the potential to become 
therapeutic targets is gradually increasing. Considering that lncRNAs function as 
decoys, regulators of translation, and scaffolds directing chromatin-modifying 
enzymes to specific genomic loci, they are an attractive class of therapeutic targets. 
The relation between HOTAIR in breast cancer [93] and MALAT1 in metastatic lung 
cancer [94] is a remarkable example of this association. Therefore, there is enthu-
siasm about the possibility to develop therapeutic tools to modulate mis-regulated 
lncRNAs in diseases. Although lncRNAs represent appealing pharmacological and 
therapeutic targets, inhibiting lncRNAs in vivo remains a challenge. A possible 
approach could be the use of small molecules that disrupt the complex lncRNA-chro-
matin that alter the epigenetic state of the target cells. All these delivery efforts, along 
with further elucidation of lncRNA regulatory mechanisms, will ultimately lead to 
the development of effective therapeutic strategies that target lncRNAs in vivo.
6. Conclusion
The impairment in RNA regulation and processing is crucial in ALS patho-
genesis. Defects at different steps of RNA processing alter both cellular function 
and survival; thus RNA metabolism can be an essential target for therapeutic 
intervention for ALS and for other NDs. The application of RNA-based therapies 
to modulate gene and protein expression is an interesting therapeutic strategy: 
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the preclinical application of RNA-based therapies targeting SOD1 and C9orf72 
mutations are promising and pave the way to apply similar approaches for FUS and 
TDP-43 mutations. In conclusion, RNA-based therapies could be recommended for 
the future treatment of ALS.
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ABLIM1 actin-binding LIM
ADORA2A adenosine A2a receptor
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